Understanding Tysabri Exposure: A Patient History Perspective

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Risk Awareness

If you or a loved one has taken Tysabri, understanding the history of medication exposure and the chronology of treatment is essential. This page provides a patient-focused overview of Tysabri use, from initiation to long-term monitoring, within the broader context of pharmaceutical risk management and patient safety.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three established risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be considered in the context of expected benefit when initiating and continuing therapy. PML typically presents with subacute neurological deficits that evolve over weeks to months. Common clinical features include cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The disease is often rapidly progressive and can lead to severe disability or death. In Tysabri-treated patients, PML may occur even in the absence of overt immunosuppression, as the drug modulates lymphocyte trafficking to the central nervous system.

Mechanism of PML in Tysabri-Treated Patients

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4 on lymphocytes, Tysabri prevents immune cells from crossing the blood-brain barrier. This reduces normal immune surveillance of the central nervous system, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. The resulting demyelination produces the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, as seropositivity indicates prior exposure to the virus. Treatment duration beyond two years further increases risk, likely due to prolonged immune suppression within the brain. FDA adverse event reports for Tysabri frequently include neurological symptoms that could overlap with early PML presentation. Among the most commonly reported events are fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms are common in multiple sclerosis itself, their presence in a Tysabri-treated patient should prompt evaluation for PML.

Regulatory Warnings and Monitoring Requirements

The adequacy of warnings regarding Tysabri and PML has been a subject of regulatory and legal scrutiny. The boxed warning is prominently displayed in the prescribing information and mandates that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution system designed to ensure informed consent and ongoing monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are required to evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to Biogen. Despite these measures, questions may arise about whether patients were adequately informed of the risk, particularly regarding the cumulative nature of risk over time and the implications of anti-JCV antibody status.

Statute of Limitations for Tysabri Claims in Texas

For patients in Texas who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For PML, the timeline between exposure and documented harm can be variable. PML typically develops after months to years of Tysabri treatment, with risk increasing significantly after two years of therapy. The latency period means that the injury may not become apparent until well after the drug was initiated. Patients and their families should be aware that the clock for filing a claim may start when PML is diagnosed or when symptoms first become attributable to the drug, rather than at the time of initial exposure. Given the severity of PML and the potential for permanent disability or death, timely legal consultation is critical to preserve the right to seek compensation for medical expenses, lost income, and pain and suffering.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for a Tysabri-related PML claim in Texas?

In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For PML, this typically means the clock starts when PML is diagnosed or when symptoms first become attributable to Tysabri, not at the time of initial exposure.

What are the main risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are identified in the Tysabri prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.